Langerhans cell histiocytosis in adults: literature review

Cover Page

Cite item

Full Text

Abstract

Langerhans cells histiocytosis is a variant of malignant histiocytosis. The course and symptoms vary. patients with localized forms have a better prognosis, because local therapy is effective. patients with multifocal forms of histiocytosis receive systemic drug therapy, which cures some of the patients. This review provides up-to-date data about typical presentation of the organ involvement, diagnosis, course and therapy of various forms of Langerhans cells histiocytosis.

About the authors

V. G. Potapenko

City Clinical Hospital No. 31

Author for correspondence.
Email: potapenko.vsevolod@mail.ru
ORCID iD: 0000-0003-2985-0503

3 Prospekt Dinamo, Saint Petersburg 197110

Russian Federation

V. V. Baykov

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-9191-5091

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

A. V. Zinchenko

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0001-5087-0192

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

N. A. Potikhonova

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency

16 2nd Sovetskaya St., Saint Petersburg 191024

Russian Federation

References

  1. Pileri S.A., Grogan T.M., Harris N.L. et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002;41(1):1–29. doi: 10.1046/j.1365­2559.2002.01418.x
  2. Howarth D.M., Gilchrist G.S., Mullan B.P. et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 1999;(85):2278–90. doi: 10.1002/(sici)1097­0142(19990515)85:10<2278::aid­cncr25>3.0.co;2­u
  3. Goyal G., Shah M.V., Hook C.C. et al. Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and longterm outcomes. Br J Haematol 2018;182(4):579–81. doi: 10.1111/bjh.14818
  4. Campo E., Harris N.L., Pileri S.A. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2017.
  5. Bykov V.L. Private human histology (short review course). Saint Petersburg, 2011. (In Russ.).
  6. Golub R., Cumano A. Embryonic hematopoiesis. Blood Cells Mol Dis 2013;51(4):226–31. doi: 10.1016/j.bcmd.2013.08.004
  7. Van de Laar L., Saelens W., De Prijck S. et al. Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue­resident macrophages. Immunity 2016;44(4):755–68. doi: 10.1016/j.immuni.2016.02.017
  8. Collin M., Milne P. Langerhans cell origin and regulation. Curr Opin Hematol 2016;23(1):28–35. doi: 10.1097/MOH.0000000000000202
  9. Langerhans P. Über die Nerven der menschlichen Haut. Arch Abl B Pathol 1868;44:325–37.
  10. Churilov L.P. Death on the rise, or Who are you, Dr. Taratynov? Zdorov’e – osnova chelovecheskogo potentsiala: problemy i puti ikh resheniya = Health is the Basis of Human Potential: Problems and Ways to Solve them 2014;9(2):919–29. (In Russ.).
  11. Coppes­Zantinga A., Egeler R.M. The Langerhans cell histiocytosis X files revealed. Br J Haematol 2002;116(1):3–9. doi: 10.1046/j.1365­2141.2002.03232.x
  12. Diamond E.L., Durham B.H., Haroche J. et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016;6(2):154–65. doi: 10.1158/2159­8290.CD­15­0913
  13. Haroche J., Charlotte F., Arnaud L. et al. High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non­Langerhans cell histiocytoses. Blood 2012;120(13):2700–3. doi: 10.1182/blood­2012­05­430140
  14. Badalian­Very G., Vergilio J.A., Degar B.A. et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116(11):1919–23. doi: 10.1182/blood­2010­04­279083
  15. Roden A.C., Hu X., Kip S. et al. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 2014;38(4):548–51. doi: 10.1097/PAS.0000000000000129
  16. Go H., Jeon Y.K., Huh J. et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 2014;65(2):261–72. doi: 10.1111/his.12416
  17. Héritier S., Emile J.F., Barkaoui M.A. et al. BRAF mutation correlates with high­risk Langerhans cell histiocytosis and increased resistance to first­line therapy. J Clin Oncol 2016;34(25):3023–30. doi: 10.1200/JCO.2015.65.9508
  18. Medeiros L.J., Miranda R.N. Diagnostic pathology: lymph nodes and extranodal lymphomas e­book. Elsevier Health Sciences, 2017.
  19. Grace S.A., Sutton A.M., Armbrecht E.S. et al. p53 is a helpful marker in distinguishing Langerhans cell histiocytosis from Langerhans cell hyperplasia. Am J Dermatopathol 2017;39(10):726–30. doi: 10.1097/DAD.0000000000000778
  20. Chatterjee D., Vishwajeet V., Saikia U.N. et al. Is useful to differentiate Langerhans cell histiocytosis from reactive Langerhans cells. Am J Dermatopathol 2019;41(3):188–92. doi: 10.1097/DAD.0000000000001250
  21. Emile J.F., Abla O., Fraitag S. et al. Revised classification of histiocytoses and neoplasms of the macrophage­dendritic cell lineages. Blood 2016;127(22):2672–81. DOI: 10.1182/ blood­2016­01­690636
  22. Aricò M., Girschikofsky M., Généreau T. et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003;39(16):2341–8. doi: 10.1016/s0959­8049(03)00672­5
  23. Potapenko V.G., Klimovich A.V., Evseev D.A. et al. Structure and clinical manifestations of malignant histiocytosis in adults. Gematologiya i transfuziologiya = Hematology and Transfusiology 2022;67(S1):186. (In Russ.).
  24. Tazi A., Marc K., Dominique S. et al. Serial CT and lung function testing in pulmonary Langerhans cell histiocytosis. Eur Respir J 2012;40(4):905–12. doi: 10.1183/09031936.00210711
  25. Colby T.V., Lombard C. Histiocytosis X in the lung. Hum Pathol 1983;14(10):847–56. doi: 10.1016/s0046­8177(83)80160­9
  26. Amosov V.V. Early radiation diagnosis and monitoring of patients with pulmonary histiocytosis. Dis. … candidate of medical sciences. Moscow, 2017. (In Russ.).
  27. Wei P., Lu H.W., Jiang S. et al. Pulmonary Langerhans cell histiocytosis: case series and literature review. Medicine (Baltimore). 2014;93(23):e141. doi: 10.1097/MD.0000000000000141
  28. Von Essen S., West W., Sitorius M. et al. Complete resolution of roentgenographic changes in a patient with pulmonary histiocytosis X. Chest 1990;98(3):765–7. doi: 10.1378/chest.98.3.765
  29. Delobbe A., Durieu J., Duhamel A. et al. Determinants of survival in pulmonary Langerhans’ cell granulomatosis (histiocytosis X). Groupe d’Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord. Eur Respir J 1996;9(10):2002–6. doi: 10.1183/09031936.96.09102002
  30. Mogulkoc N., Veral A., Bishop P.W. et al. Pulmonary Langerhans’ cell histiocytosis: radiologic resolution following smoking cessation. Chest 1999;115(5):1452–5. doi: 10.1378/chest.115.5.1452
  31. Sawalha L., Kumar A., Arshad A. et al. Pulmonary Langerhans cell histiocytosis: radiologic resolution following cessation of second hand smoking. Clin Respir J 2017;11(6):1063–7. doi: 10.1111/crj.12445
  32. Vassallo R., Harari S., Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax 2017;72(10):937–45. doi: 10.1136/thoraxjnl­2017­210125
  33. Liu H., Osterburg A.R., Flury J. et al. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. JCI Insight 2020;5(4):e13204. doi: 10.1172/jci.insight.132048
  34. Mendez J.L., Nadrous H.F., Vassallo R. et al. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest 2004;125(3):1028–32. doi: 10.1378/chest.125.3.1028
  35. Mason R.H., Foley N.M., Branley H.M. et al. Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register. Thorax 2014;69(8):766–7. doi: 10.1136/thoraxjnl­2013­204313
  36. Tadokoro A., Ishii T., Bandoh S. et al. Pulmonary Langerhans cell histiocytosis in a non­smoking Japanese woman. Nihon Kokyuki Gakkai Zasshi 2011;49(3):203–7.
  37. Fernandes L., Vadala R., Mesquita A.M. et al. Rare interstitial lung disease: pulmonary Langerhans cell histiocytosis in a young non smoking Indian female. Indian J Tuberc 2015;62(1):46–9. doi: 10.1016/j.ijtb.2015.02.008
  38. Marchal J., Kambouchner M., Tazi A. et al. Expression of apoptosis­regulatory proteins in lesions of pulmonary Langerhans cell histiocytosis. Histopathology 2004;45(1):20–8. doi: 10.1111/j.1365­2559.2004.01875.x
  39. Hogstad B., Berres M.L., Chakraborty R. et al. RAF/MEK/ extracellular signal­related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 2018;215(1):319–36. doi: 10.1084/jem.20161881
  40. Samsonova M.V., Chernyaev A.L., Avdeev S.N. et al. Relapse of Langerhans cell histiocytosis after lung transplantation. Prakticheskaya pul’monologiya = Practical Pulmonology 2018;(4):81–5. (In Russ.).
  41. Dauriat G., Mal H., Thabut G. et al. Lung transplantation for pulmonary Langerhans’ cell histiocytosis: a multicenter analysis. Transplantation 2006;81(5):746–50. doi: 10.1097/01. tp.0000200304.64613.af
  42. Housini I., Tomashefski J.F.Jr, Cohen A. et al. Transbronchial biopsy in patients with pulmonary eosinophilic granuloma. Comparison with findings on open lung biopsy. Arch Pathol Lab Med 1994;118(5):523–30.
  43. Auerswald U., Barth J., Magnussen H. Value of CD­1­positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X. Lung 1991;169(6):305–9. DOI: 10.1007/ BF02714167
  44. Girschikofsky M., Arico M., Castillo D. et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro­Histio­Net. Orphanet J Rare Dis 2013;(8):72. doi: 10.1186/1750­1172­8­72
  45. Casolaro M.A., Bernaudin J.F., Saltini C. et al. Accumulation of Langerhans’cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988;137(2):406–11. doi: 10.1164/ajrccm/137.2.406
  46. Radzikowska E., Błasińska­Przerwa K., Wiatr E. et al. Pneumothorax in patients with pulmonary Langerhans cell histiocytosis. Lung 2018;196(6):715–20. doi: 10.1007/s00408­018­0155­1
  47. Singla A., Kopras E.J., Gupta N. Spontaneous pneumothorax and air travel in pulmonary Langerhans cell histiocytosis: a patient survey. Respir Investig 2019;57(6):582–9. DOI: 10.1016/j. resinv.2019.07.004
  48. Chaowalit N., Pellikka P.A., Decker P.A. et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004;79(10):1269–75. doi: 10.4065/79.10.1269
  49. Wajda N., Zhu Z., Jandarov R. et al. Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis. Respirology 2020;25(6):644–50. doi: 10.1111/resp.13671
  50. Singh A., Prieto V.G., Czelusta A. et al. Adult Langerhans cell histiocytosis limited to the skin. Dermatology 2003;207(2):157–61. doi: 10.1159/000071786
  51. Caputo R., Gianotti R., Monti M. Nodular “pure” mucocutaneous histiocytosis X in an adult. Arch Dermatol 1987;123(10):1274–5.
  52. Chi D.H., Sung K.J., Koh J.K. Eruptive xanthoma­like cutaneous Langerhans cell histiocytosis in an adult. J Am Acad Dermatol 1996;34(4):688–9. doi: 10.1016/s0190­9622(96)80088­0
  53. Lieberman P.H., Jones C.R., Steinman R.M. et al. Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol 1996;20(5):519–52. doi: 10.1097/00000478­199605000­00001
  54. Yusupova L.A., Yunusova E.I., Garaeva Z.Sh. et al. Histiocytosis X. Prakticheskaya meditsina = Practical Medicine 2014;8(84):7–10. (In Russ.).
  55. Lichtenwald D.J., Jakubovic H.R., Rosenthal D. Primary cutaneous Langerhans cell histiocytosis in an adult. Arch Dermatol 1991;127(10):1545–8.
  56. Hashimoto K., Kagetsu N., Taniguchi Y. et al. Immunohistochemistry and electron microscopy in Langerhans cell histiocytosis confined to the skin. J Am Acad Dermatol 1991;25(6 Pt 1): 1044–53. doi: 10.1016/0190­9622(91)70305­l
  57. Kunst M.A., Akhmerov S.F., Badeeva M.Yu. et al. A case of cutaneous Langerhans cell histiocytosis (Histiocytosis X). Prakticheskaya meditsina = Practical Medicine 2011;(55):195–7. (In Russ.).
  58. Reisi N., Raeissi P., Harati Khalilabad T. et al. Unusual sites of bone involvement in Langerhans cell histiocytosis: a systematic review of the literature. Orphanet J Rare Dis 2021;16(1):1. doi: 10.1186/s13023­020­01625­z
  59. Salam H., Shahid R., Mirza T. Langerhans cell histiocytosis involving both jaws in an adult. J Coll Physicians Surg Pak 2017;27(9):S89–91.
  60. Saunders J.G., Eveson J.W., Addy M. et al. Langerhans cell histiocytosis presenting as bilateral eosinophilic granulomata in the molar region of the mandible. A case report. J Clin Periodontol 1998;25(4):340–2. doi: 10.1111/j.1600­051x.1998.tb02451.x
  61. Peters S.M., Pastagia J., Yoon A.J. et al. Langerhans cell histiocytosis mimicking periapical pathology in a 39­year­old man. J Endod 2017;43(11):1909–14. doi: 10.1016/j.joen.2017.05.020
  62. Nangalia R., Chatterjee R.P., Kundu S. et al. Langerhans cell histiocytosis in an adult with oral cavity involvement: posing a diagnostic challenge. Contemp Clin Dent 2019;10(1):154–7. doi: 10.4103/ccd.ccd_432_18
  63. Eckardt A., Schultze A. Maxillofacial manifestations of Langerhans cell histiocytosis: a clinical and therapeutic analysis of 10 patients. Oral Oncol 2003;39(7):687–94. doi: 10.1016/s13688375(03)00080­0
  64. Kim J.E., Yi W.J., Heo M.S. et al. Langerhans cell histiocytosis of the jaw, a mimicker of osteomyelitis on CT and MR images: a retrospective analysis. Medicine (Baltimore) 2019;98(27):e16331. doi: 10.1097/MD.0000000000016331
  65. Diab A., Daihes N.A., Saidulaev V.A. et al. Langerhans cell histiocytosis of the temporal bones: a clinical case. Vrach = The Doctor 2022;(1):78–80. (In Russ.). doi: 10.29296/25877305­2022­01­13
  66. Dogan A.S., Conway J.J., Miller J.H. et al. Detection of bone lesions in Langerhans cell histiocytosis: complementary roles of scintigraphy and conventional radiography. J Pediatr Hematol Oncol 1996;18(1):51–8. doi: 10.1097/00043426­199602000­00010
  67. Goo H.W., Yang D.H., Ra Y.S. et al. Whole­body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol 2006;36(10):1019–31. doi: 10.1007/s00247­006­0246­7
  68. Kim J.R., Yoon H.M., Jung A.Y. et al. Comparison of whole­body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans cell histiocytosis. Sci Rep 2019;9(1):317. doi: 10.1038/s41598­018­36501­1
  69. Jessop S., Crudgington D., London K. et al. FDG PET­CT in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer 2020;67(1):e28034. doi: 10.1002/pbc.28034
  70. Ferrell J., Sharp S., Kumar A. et al. Discrepancies between F­18­FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis. Pediatr Blood Cancer 2021;68(4):e28891. doi: 10.1002/pbc.28891
  71. Mayer S., Raggio B.S., Master A. et al. Langerhans cell histiocytosis of the temporal bone. Ochsner J 2020;20(3):315–8. DOI: 10.31486/ toj.19.0032
  72. Coleman M.A., Matsumoto J., Carr C.M. et al. Bilateral temporal bone langerhans cell histiocytosis: radiologic pearls. Open Neuroimag J 2013;7:53–7. doi: 10.2174/1874440001307010053
  73. Modest M.C., Garcia J.J., Arndt C.S. et al. Langerhans cell histiocytosis of the temporal bone: a review of 29 cases at a single center. Laryngoscope 2016;126(8):1899–904. doi: 10.1002/lary.25773
  74. Key S.J., O’Brien C.J., Silvester K.C. et al. Eosinophilic granuloma: resolution of maxillofacial bony lesions following minimal intervention. Report of three cases and a review of the literature. J Craniomaxillofac Surg 2004;32(3):170–5. DOI: 10.1016/j. jcms.2004.01.004
  75. Vaish A., Vaishya R., Singh L.K. et al. Langerhans cell histiocytosis of a metatarsal bone in an adult female. BMJ Case Rep 2019;12(10):e231343. doi: 10.1136/bcr­2019­231343
  76. Miller M.A., Williams W.W. Eosinophilic granuloma of the hand. J Hand Surg Br 1993;18(6):742–5. doi: 10.1016/02667681(93)90234­7
  77. Rimondi E., Mavrogenis A.F., Rossi G. et al. CT­guided corticosteroid injection for solitary eosinophilic granuloma of the spine. Skeletal Radiol 2011;40(6):757–64. doi: 10.1007/s00256010­1045­7
  78. Mavrogenis A.F., Rimondi E., Ussia G. et al. Successful treatment of a bifocal eosinophilic granuloma of the spine with CT­guided corticosteroid injection. Orthopedics 2011;34(3):230. doi: 10.3928/01477447­20110124­29
  79. Esen A., Dolanmaz D., Kalayci A. et al. Treatment of localized Langerhans’ cell histiocytosis of the mandible with intralesional steroid injection: report of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109(2):e53–8. doi: 10.1016/j.tripleo.2009.10.015
  80. Kotecha R., Venkatramani R., Jubran R.F. et al. Clinical outcomes of radiation therapy in the management of Langerhans cell histiocytosis. Am J Clin Oncol 2014;37(6):592–6. DOI: 10.1097/ COC.0b013e318281d6ce
  81. Latyshev V.D., Lukina E.A. Langerhans cell histiocytosis in adults: modern possibilities of therapy. Klinicheskaya onkogematologiya = Clinical Oncohematology 2021;14(4):444–54. (In Russ.). doi: 10.21320/2500­2139­2021­14­4­444­45
  82. Laird J., Ma J., Chau K. et al. Outcome after radiation therapy for langerhans cell histiocytosis is dependent on site of involvement. Int J Radiat Oncol Biol Phys 2018;100(3):670–8. doi: 10.1016/j.ijrobp.2017.10.053
  83. Grois N., Fahrner B., Arceci R.J. et al. Histiocyte Society CNS LCH Study Group. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010;156(6):873–81.e1. DOI: 10.1016/j. jpeds.2010.03.001
  84. A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans’ Cell Histiocytosis Study Group. Arch Dis Child 1996;75(1):17–24. doi: 10.1136/adc.75.1.17
  85. Dhall G., Finlay J.L., Dunkel I.J. et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2­chlorodeoxyadenosine. Pediatr Blood Cancer 2008;50(1):72–9. doi: 10.1002/pbc.21225
  86. Lukina L.V., Mikhailov V.A., Anan’eva N.I. et al. A case of fixation amnesia in histiocytosis from Langerhans cells with damage to the central nervous system. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(6):117–23. (In Russ.). doi: 10.14412/2074­2711­2020­6­117­123
  87. Rumboldt Z., Rossi A. Neurodegenerative Langerhans Cell Histiocytosis (ND­LCH). In: Brain Imaging with MRI and CT: An Image Pattern Approach. Eds.: Z. Rumboldt, M. Castillo, B. Huang et al. Cambridge: Cambridge University Press, 2012. Pp. 71–72. doi: 10.1017/CBO9781139030854.036
  88. Wnorowski M., Prosch H., Prayer D. et al. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J Pediatr 2008;153(1):127–32. doi: 10.1016/j.jpeds.2007.12.042
  89. Latyshev V.D., Chavynchak R.B., Kovrigina A.M. et al. Histiocytosis – timing of diagnosis and demographic characteristics of patients, the experience of the Hematology Research Institute. Materials of the V Congress of Hematologists of Russia. Gematologiya i transfuziologiya = Hematology and Transfusiology 2020;65:164 (In Russ.).
  90. Makras P., Terpos E., Kanakis G. et al. Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2012;58(5):819–22. doi: 10.1002/pbc.23166
  91. Alexandraki K.I., Makras P., Protogerou A.D. et al. Cardiovascular risk factors in adult patients with multisystem Langerhans­cell histiocytosis: evidence of glucose metabolism abnormalities. QJM 2008;101(1):31–40. doi: 10.1093/qjmed/hcm118
  92. Kaltsas G.A., Powles T.B., Evanson J. et al. Hypothalamo­pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab 2000;85(4):1370–6. doi: 10.1210/jcem.85.4.6501
  93. Ma J., Jiang Y., Chen X. et al. Langerhans cell histiocytosis misdiagnosed as liver cancer and pituitary tumor in an adult: а case report and brief review of the literature. Oncol Lett 2014;7(5): 1602–4. doi: 10.3892/ol.2014.1928
  94. Mampaey S., Warson F., Van Hedent E. et al. Imaging findings in Langerhans’ cell histiocytosis of the liver and the spleen in an adult. Eur Radiol 1999;9(1):96–8. doi: 10.1007/s003300050636
  95. König C.W., Pfannenberg C., Trübenbach J. et al. MR cholangiography in the diagnosis of sclerosing cholangitis in Langerhans’ cell histiocytosis. Eur Radiol 2001;11(12):2516–20. doi: 10.1007/s003300100835
  96. Arakawa A., Matsukawa T., Yamashita Y. et al. Periportal fibrosis in Langerhans’ cell histiocytosis mimicking multiple liver tumors: US, CT, and MR findings. J Comput Assist Tomogr 1994;18(1):157–9. doi: 10.1097/00004728­199401000­00037
  97. Hong L., Sun G., Peng L. et al. Isolated Langerhans cell histiocytosis of the spleen: a case report. Medicine (Baltimore) 2018;97(38):e12378. doi: 10.1097/MD.0000000000012378
  98. Singhi A.D., Montgomery E.A. Gastrointestinal tract langerhans cell histiocytosis: a clinicopathologic study of 12 patients. Am J Surg Pathol 2011;35(2):305–10. doi: 10.1097/PAS.0b013e31820654e4
  99. Geissmann F., Thomas C., Emile J.F. et al. Digestive tract involvement in Langerhans cell histiocytosis. The French Langerhans Cell Histiocytosis Study Group. J Pediatr 1996;129(6):836–45. doi: 10.1016/s0022­3476(96)70027­6
  100. Hamdan M., Qiao J.C., Fikfak V. Adult­onset perianal Langerhans cell histiocytosis presenting as pruritus ani: a case report and review of the literature. J Med Case Rep 2021;15(1):357. DOI: 10.1186/ s13256­021­02924­0
  101. Shankar U., Prasad M., Chaurasia O.P. A rare case of langerhans cell histiocytosis of the gastrointestinal tract. World J Gastroenterol 2012;18(12):1410–3. doi: 10.3748/wjg.v18.i12.1410
  102. Edelweiss M., Medeiros L.J., Suster S. et al. Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol 2007;38(10):1463–9. doi: 10.1016/j.humpath.2007.03.015
  103. Lo W.C., Chen C.C., Tsai C.C. et al. Isolated adult Langerhans’ cell histiocytosis in cervical lymph nodes: should it be treated? J Laryngol Otol 2009;123(9):1055–7. doi: 10.1017/S0022215108004155
  104. Guo J.J., Zhu H.Y., Wang L. et al. The clinical and laboratory characteristics of adult Langerhans cell histiocytosis patients and the influencing factors of prognosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020;28(6):2079–83. doi: 10.19746/j.cnki.issn.10092137.2020.06.046
  105. Haupt R., Minkov M., Astigarraga I. et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work­up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 2013;60(2):175–84. doi: 10.1002/pbc.24367
  106. Cao X.X., Li J., Zhao A.L. et al. Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: a single arm, single center, prospective phase 2 study. Am J Hematol 2020;95(9):E235–8. doi: 10.1002/ajh.25864
  107. Magaton I.M., Tzankov A., Krasniqi F. et al. Spontaneous remission of severe systemic Langerhans cell histiocytosis with bladder involvement: a case study. Case Rep Oncol 2017;10(3):876–84. doi: 10.1159/000480696
  108. Gnanasekhar J.D., Ahmad M.S., Reddy R.R. Multifocal Langerhans cell histiocytosis of the jaws: a case report. Quintessence Int 1991;22(7):559–64.
  109. Shteinberg M., Yeremekno D., Adir Y. Spontaneous resolution of pulmonary Langerhans cell histiocytosis despite smoking. Lung 2016;194(2):331–2. doi: 10.1007/s00408­016­9845­8
  110. Histiocytosis Association. Langerhans cell histiocytosis in children. Available at: https://www.histio.org/page.aspx?pid=380.
  111. Steen A.E., Steen K.H., Bauer R. et al. Successful treatment of cutaneous Langerhans cell histiocytosis with low­dose methotrexate. Br J Dermatol 2001;145(1):137–40. doi: 10.1046/j.1365­2133.2001.04298.x
  112. Zinn D.J., Grimes A.B., Lin H. et al. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood 2016;128(20): 2462–5. doi: 10.1182/blood­2016­06­721993
  113. Farrugia M.K., Morrison C., Hernandez­Ilizaliturri F. et al. A doseresponse relationship to radiotherapy for cutaneous lesions of Langerhans cell histiocytosis. Case Rep Oncol Med 2021;2021:6680635. doi: 10.1155/2021/6680635
  114. Nakajima K., Morisawa R., Kodama H. et al. Successful treatment with cyclophosphamide of Langerhans cell histiocytosis involving the skin and lymph nodes in an adult patient. Clin Exp Dermatol 2010;35(7):791–2. doi: 10.1111/j.1365­2230.2010.03802.x
  115. Chang S.E., Koh G.J., Choi J.H. et al. Widespread skin­limited adult Langerhans cell histiocytosis: long­term follow­up with good response to interferon alpha. Clin Exp Dermatol 2002;27(2):135–7. doi: 10.1046/j.1365­2230.2002.00989.x
  116. Rees J., Paterson A.W. Langerhans cell histiocytosis in an adult. Br J Oral Maxillofac Surg 2009;47(1):52–3. doi: 10.1016/j.bjoms. 2008.04.010
  117. Salama H.A., Jazieh A.R., Alhejazi A.Y. et al. Highlights of the management of adult histiocytic disorders: Langerhans cell histiocytosis, Erdheim–Chester disease, Rosai–Dorfman disease, and hemophagocytic lymphohistiocytosis. Clin Lymphoma Myeloma Leuk 2021;21(1):e66–75. doi: 10.1016/j.clml.2020.08.007
  118. Allen C.E., Ladisch S., McClain K.L. How I treat Langerhans cell histiocytosis. Blood 2015;126(1):26–35. doi: 10.1182/blood­2014­12­569301
  119. Go R.S., Jacobsen E., Baiocchi R. et al. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(11):1277–303. doi: 10.6004/jnccn.2021.0053
  120. Carrera C.J., Terai C., Lotz M. et al. Potent toxicity of 2–chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest 1990;86(5):1480–8. doi: 10.1172/JCI114865
  121. Goyal G., Abeykoon J.P., Hu M. et al. Single­agent cladribine as an effective front­line therapy for adults with Langerhans cell histiocytosis. Am J Hematol 2021;96(5):E146–50. doi: 10.1002/ajh.26119
  122. Adam Z., Szturz P., Duraš J. et al. Léčba histiocytózy z Langerhansových buněk kladribinem dosáhla u 9 z 10 dospělých pacientů dlouhodobé kompletní remise [Treatment of Langerhans cells histiocytosis by cladribin reached long–term complete remission in 9 out of 10 adult patients (In Czech)]. Klin Onkol 2012;25(4):255–61.
  123. Saven A., Burian C. Cladribine activity in adult Langerhans­cell histiocytosis. Blood 1999;93(12):4125–30.
  124. Néel A., Artifoni M., Fontenoy A.M. et al. Long­term efficacy and safety of 2CdA (cladribine) in extra­pulmonary adult­onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. Br J Haematol 2020;189(5):869–78. doi: 10.1111/bjh.16449
  125. Cytarabine. Instructions for use. Available at: https://www.rlsnet.ru/drugs/citarabin–798. (In Russ.).
  126. Ogura M., Morishima Y., Kobayashi Y. et al. Cladribine Study Group. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non­Hodgkin’s lymphomas: results of a Japanese phase II study. Int J Hematol 2004;80(3):267–77. doi: 10.1532/ijh97.04077
  127. Cantu M.A., Lupo P.J., Bilgi M. et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One 2012;7(8):e43257. doi: 10.1371/journal.pone.0043257
  128. Martin M., Pennington K., Vassallo R. Pulmonary Langerhans cell histiocytosis: is marijuana smoking a risk factor? Teasers in diffuse lung disease, 2020. Abstract A3303. doi: 10.1164/ajrccmconference.2020.201.1_MeetingAbstracts.A3303
  129. Rumyantsev A.G., Maschan A.A., Maschan M.A. et al. Federal clinical guidelines for the treatment of LCH in children. Moscow, 2015. (In Russ.).
  130. Radzikowska E., Wiatr E., Bestry I. et al. The results of treatment with vinbalstine prednisone and mercaptopurine in adult patients with multisystem langerhans cell histiocytosis. Pediatric Blood Cancer 2014;61(11):2138.
  131. Tazi A., Lorillon G., Haroche J. et al. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis 2017;12(1):95. doi: 10.1186/s13023­017­0651­z
  132. Duan M.H., Han X., Li J. et al. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first­line treatment for adult Langerhans cell histiocytosis: a single­center retrospective study. Leuk Res 2016;42:43–6. doi: 10.1016/j.leukres.2016.01.012
  133. Kemps P.G., Picarsic J., Durham B.H. et al. ALK­positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 2022;139(2):256–80. doi: 10.1182/blood.2021013338
  134. Diamond E.L., Subbiah V., Lockhart A.C. et al. Vemurafenib for BRAF V600­mutant Erdheim–Chester disease and Langerhans cell histiocytosis: analysis of data from the histology­independent, phase 2, open­label VE­BASKET study. JAMA Oncol 2018;4(3):384–8. doi: 10.1001/jamaoncol.2017.5029
  135. Latyshev V.D., Chavynchak R.D., Averbukh O.M. et al. Trametinib therapy for Langerhans cell histiocytosis and Erdheim–Chester disease in adults. Materials of the VI Congress of Hematologists of Russia. Gematologiya i transfuziologiya = Hematology and Transfusiology 2022;67(S1):50. (In Russ.).
  136. Hazim A.Z., Ruan G.J., Ravindran A. et al. Efficacy of BRAF­Inhibitor therapy in BRAFV600E­mutated adult Langerhans cell histiocytosis. Oncologist 2020;25(12):1001–4. doi: 10.1002/onco.13541
  137. Morrison S., Gray A., Greiling T.M. Improvement of primary vulvar Langerhans cell histiocytosis with lenalidomide. Int J Womens Dermatol 2021;7(5Part B):838–40. DOI: 10.1016/j. ijwd.2021.09.010
  138. Lair G., Marie I., Cailleux N. et al. Histiocytose langerhansienne de l’adulte: localisations cutanéomuqueuses régressives après traitement par thalidomide [Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide (In French)]. Rev Med Interne 1998;19(3):196–8. doi: 10.1016/s0248­8663(97)80720­5
  139. Alioua Z., Hjira N., Oumakhir S. et al. Efficacité du thalidomide dans le traitement de l’histiocytose langerhansienne multisystémique de l’adulte: à propos d’une observation [Thalidomide in adult multisystem Langerhans cell histiocytosis: a case report (In French)]. Rev Med Interne 2006;27(8):633–6. doi: 10.1016/j.revmed.2006.01.022
  140. Jacobsen E., Redd R., Nicotra A. et al. A phase II trial of lenalidomide in adults with histiocyte disorders. Pediatric Blood Cancer 2017;64:S14–5. doi: 10.1002/pbc.26770
  141. Da Costa C.E., Annels N.E., Faaij C.M. et al. Presence of osteoclast­like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med 2005;201(5):687–93. doi: 10.1084/jem.20041785
  142. Chellapandian D., Makras P., Kaltsas G. et al. Bisphosphonates in Langerhans cell histiocytosis: an international retrospective case series. Mediterr J Hematol Infect Dis 2016;8(1):e2016033. doi: 10.4084/MJHID.2016.033
  143. Montella L., Merola C., Merola G. et al. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab 2009;27(1):110–3. doi: 10.1007/s00774­008­0001­2
  144. Makras P., Tsoli M., Anastasilakis A.D. et al. Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. Metabolism 2017;69:107–11. doi: 10.1016/j.metabol.2017.01.004
  145. Arenzana­Seisdedos F., Barbey S., Virelizier J.L. et al. Histiocytosis X. Purified (T6+) cells from bone granuloma produce interleukin 1 and prostaglandin E2 in culture. J Clin Invest 1986;77(1):326–9. doi: 10.1172/JCI112296
  146. De Benedittis D., Mohamed S., Rizzo L. et al. Indomethacin is an effective treatment in adults and children with bone Langerhans cell histiocytosis (LCH). Br J Haematol 2020;191(5):e109–13. doi: 10.1111/bjh.17067

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.